Talapo Therapeutics has a portfolio of biologic agents that could transform how obesity and its related complications are treated. Our human-derived, protein-based agents target pathways with key roles in adipose tissue development, turnover, homeostasis, or function. Talspo agents block new fat cell formation, reduce lipid accumulation in fat and liver cells, and limit growth of fat depots in mice. Talapo agents are produced using standard biotechnology approaches. We have developed biophysical and biological activity benchmarks, including surface plasmon resonance, reporter gene expression, and fat cell differentiation assays that ensure the reproducibility and quality of each one of our agents. The team has deep knowledge of the pathway and strong expertise in the manufacturing and scalability of Talapo agents.
Based on their mechanism of action, our agents offer opportunities for treating obesity and its associated complications, including NASH and T2D.